Publication date: Feb 07, 2020
While molecular-targeted drugs have demonstrated strong therapeutic efficacy against diverse diseases such as cancer and infection, the appearance of drug resistance associated with genetic variations in individual patients or pathogens has severely limited their clinical efficacy. Therefore, precision medicine approaches based on the personal genomic background provide promising strategies to enhance the effectiveness of molecular-targeted therapies. However, identifying drug resistance mutations in individuals by combining DNA sequencing and in vitro analyses is generally time consuming and costly. In contrast, in silico computation of protein-drug binding free energies allows for the rapid prediction of drug sensitivity changes associated with specific genetic mutations. Although conventional alchemical free energy computation methods have been used to quantify mutation-induced drug sensitivity changes in some protein targets, these methods are often adversely affected by free energy convergence. In this paper, we demonstrate significant improvements in prediction performance and free energy convergence by employing an alchemical mutation protocol, MutationFEP, which directly estimates binding free energy differences associated with protein mutations in three types of a protein and drug system. The superior performance of MutationFEP appears to be attributable to its more-moderate perturbation scheme. Therefore, this study provides a deeper level of insight into computer-assisted precision medicine.
Open Access PDF
Ono, F., Chiba, S., Isaka, Y., Matsumoto, S., Ma, B., Katayama, R., Araki, M., and Okuno, Y. Improvement in predicting drug sensitivity changes associated with protein mutations using a molecular dynamics based alchemical mutation method. 06303. 2020 Sci Rep (10):1.
- M3C: Monte Carlo reference-based consensus clustering.
- RefDNN: a reference drug based neural network for more accurate prediction of anticancer drug resistance.
- Molecular profiling for precision cancer therapies
- Molecular profiling for precision cancer therapies.
- Clinical Genome Data Model (cGDM) provides Interactive Clinical Decision Support for Precision Medicine.